List of Rydapt drug patents

Rydapt is owned by Novartis.

Rydapt contains Midostaurin.

Rydapt has a total of 3 drug patents out of which 1 drug patent has expired.

Expired drug patents of Rydapt are:

  • US8222244

Rydapt was authorised for market use on 28 April, 2017.

Rydapt is available in capsule;oral dosage forms.

Rydapt can be used as treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl).

The generics of Rydapt are possible to be released after 02 December, 2030.

RYDAPT Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222244 NOVARTIS Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
Oct, 2022

(4 months ago)

US7973031 NOVARTIS Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
Oct, 2028

(5 years from now)

US8575146 NOVARTIS Pharmaceutical uses of staurosporine derivatives
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 28, 2024

Drugs and Companies using MIDOSTAURIN ingredient

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy; Treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl)

Dosage: CAPSULE;ORAL

How can I launch a generic of RYDAPT before it's patent expiration?
More Information on Dosage

RYDAPT family patents

10

United States

4

China

4

European Union

3

Japan

3

Canada

3

Australia

2

Portugal

2

Germany

2

Spain

2

Brazil

2

Austria

2

Mexico

2

Taiwan, Province of China

2

Korea, Republic of

2

Hong Kong

2

Hungary

2

Slovenia

2

Poland

2

Denmark

1

Russia

1

New Zealand

1

Norway

1

South Africa

1

Cyprus

1

Luxembourg

1

Israel

1

Netherlands

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in